Is it the same slow walk of the FDA? Maybe it is what we all fell for in a enthusiastic Nader leading us with just what we wanted to hear. I am guilty of this as much as anyone. I let Nader get me excited at the possibilities and ran the numbers of what Leronlimab could actual achieve if everything Nader said would come true. Not saying he lied to us. Because I don’t feel he lied to us. I feel he pushed the best case scenario always and used what would be the minimal or smallest group of trial patients possible because that’s what we could afford. It’s hard to show statistical significance when you are running on are minimums of patients needed. So was it more Naders excitement or the FDA slow walking? I would say maybe a little of both but would lay the blame on us all for listening to a pumped up narrative that Nader would accept and sell us and the FDA would scoff at and say show us more. We all share the blame and we should of reigned in Nader much sooner maybe? Hindsight is always 20/20.
I will give credit to Nader for opening up the possibilities that will keep me invested in CYDY. He has opened up the possibilities of a platform drug that we had no clue of other than what ohm had shown us was possible. Nader explored the other indications and made it believable and that most certainly that Leronlimab is definitely a platform drug. For this reason alone we all owe Nader our thanks. This is still a work in progress. Can we or will we get over the hump sooner than later? I believe we have a drug that others are realizing in the pharmaceutical arena is and will have a large impact still.
The future isn’t written yet but what I see still is potential and a company that doesn’t want to go it alone anymore. A few partnerships are likely to get us our first approval. It looks like HIV isn’t this year now. A BTD for mTNBC is off the table and looking at another trial accordingly to Dr Kelly today. Not enough data Dr. Kelly stated. Was enough for Nader but the company line now is partner with phase2 results with someone that can provide the funds to a phase 3 trial. I don't want to speculate about what happened to our 28 patients and if we surpassed Trodelvy. Because the path has been set now and we will follow the science yet again. Maybe someday we will know what happened there. Until there we are following oncology indications that have an unmet medical need and can deliver a possible quick phase 3 trial with the right partner and maybe the right drug to complement Leronlimab. Mono in cancer indications was probably just a dream and trying different therapy drugs might help us in oncology.
What it boils down to me… is we need one partnership to be our saving grace and we will have something special still in Leronlimab. We know it works. There is no doubt. We know it works for more than one indication and has different MOA for each indication we have found that… it has shown a science based guaranteed results. Do we continue to worry? It’s not if anymore… it’s when. That’s what I keep telling myself. I also remind myself it could be earlier than later with a bigger budget and enough patients to get substantial results that are undeniable. We just didn’t have the money to get’er done. Hindsight is a bitch sometimes when the cloud we were riding was so soft and cushy.
Some will re-evaluate and maybe move on. For some there is no doubt what we have and will stay until we cross the finish line. I am up for finishing this story. The longer I am around the more dedicated I become to finish. That’s the definition of a long.
I will give credit to Nader for opening up the possibilities that will keep me invested in CYDY. He has opened up the possibilities of a platform drug that we had no clue of other than what ohm had shown us was possible. Nader explored the other indications and made it believable and that most certainly that Leronlimab is definitely a platform drug. For this reason alone we all owe Nader our thanks. This is still a work in progress. Can we or will we get over the hump sooner than later? I believe we have a drug that others are realizing in the pharmaceutical arena is and will have a large impact still.
The future isn’t written yet but what I see still is potential and a company that doesn’t want to go it alone anymore. A few partnerships are likely to get us our first approval. It looks like HIV isn’t this year now. A BTD for mTNBC is off the table and looking at another trial accordingly to Dr Kelly today. Not enough data Dr. Kelly stated. Was enough for Nader but the company line now is partner with phase2 results with someone that can provide the funds to a phase 3 trial. I don't want to speculate about what happened to our 28 patients and if we surpassed Trodelvy. Because the path has been set now and we will follow the science yet again. Maybe someday we will know what happened there. Until there we are following oncology indications that have an unmet medical need and can deliver a possible quick phase 3 trial with the right partner and maybe the right drug to complement Leronlimab. Mono in cancer indications was probably just a dream and trying different therapy drugs might help us in oncology.
What it boils down to me… is we need one partnership to be our saving grace and we will have something special still in Leronlimab. We know it works. There is no doubt. We know it works for more than one indication and has different MOA for each indication we have found that… it has shown a science based guaranteed results. Do we continue to worry? It’s not if anymore… it’s when. That’s what I keep telling myself. I also remind myself it could be earlier than later with a bigger budget and enough patients to get substantial results that are undeniable. We just didn’t have the money to get’er done. Hindsight is a bitch sometimes when the cloud we were riding was so soft and cushy.
Some will re-evaluate and maybe move on. For some there is no doubt what we have and will stay until we cross the finish line. I am up for finishing this story. The longer I am around the more dedicated I become to finish. That’s the definition of a long.
9
1
